Acknowledgements
This work was made possible by grant no. MH 092435 from the National Institutes of Mental Health and the Sidney R. Baer, Jr. Foundation. It was also supported by grant no. P30DK056341 from the National Institute of Diabetes and Digestive and Kidney Diseases; grant no. UL1RR024992 from the National Center for Research Resources, a component of the National Institutes of Health and its Roadmap for Medical Research; and the Taylor Family Institute for Innovative Psychiatric Research. Special thanks to Amanda Ricchio for administrative assistance and to Katie Keenoy for assistance with manuscript development.
Notes
[1] Disclosures Dr. Nicol reports grants from Brain & Behavior Research Foundation, grants from Otsuka, and personal fees from serving as a consultant to litigation, outside the submitted work.
Dr. Lenze reports grants from NIH (NIA, NCCIH, NIMH, OBSSR), grants from FDA, grants from McKnight Brain Research Foundation, grants from Taylor Family Institute for Innovative Psychiatric Research, grants from Barnes Jewish Foundation, grants from Takeda, grants from Lundbeck, outside the submitted work.
Dr. Wilfley reports grants and personal fees from Shire Pharmaceuticals, outside the submitted work; and Dr. Wilfley is a consultant for Sunovion Pharmaceuticals.
[2] Ethics All participants provided assent, and their legal guardian provided informed consent, in accordance with the Helsinki Declaration concerning Human and Animal Rights.
The research study was approved by the Washington University Institutional Review Board, which ensures the ethical conduct of research conducted with humans and animals.